Clinical Trials
2 trialsNCT06680739 2026-06-01
SERPENTINE
Vall d'Hebron Institute of Oncology
Phase 2 Recruiting
NCT04034927 2026-05-28
Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer
National Cancer Institute (NCI)
Phase 2 Active not recruiting